365 related articles for article (PubMed ID: 25587040)
1. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.
Dhédin N; Huynh A; Maury S; Tabrizi R; Beldjord K; Asnafi V; Thomas X; Chevallier P; Nguyen S; Coiteux V; Bourhis JH; Hichri Y; Escoffre-Barbe M; Reman O; Graux C; Chalandon Y; Blaise D; Schanz U; Lhéritier V; Cahn JY; Dombret H; Ifrah N;
Blood; 2015 Apr; 125(16):2486-96; quiz 2586. PubMed ID: 25587040
[TBL] [Abstract][Full Text] [Related]
2. Minimal residual disease-based effect and long-term outcome of first-line dasatinib combined with chemotherapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Yoon JH; Yhim HY; Kwak JY; Ahn JS; Yang DH; Lee JJ; Kim SJ; Kim JS; Park SJ; Choi CW; Eom HS; Park SK; Choi SY; Kim SH; Kim DW; Lee S
Ann Oncol; 2016 Jun; 27(6):1081-1088. PubMed ID: 26951627
[TBL] [Abstract][Full Text] [Related]
3. SCT in high-risk Ph-negative adult ALL.
Blood; 2015 Apr; 125(16):2586. PubMed ID: 25883231
[No Abstract] [Full Text] [Related]
4. Finally moving forward in adult ALL.
Litzow MR
Blood; 2015 Apr; 125(16):2453-4. PubMed ID: 25883226
[TBL] [Abstract][Full Text] [Related]
5. Oncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.
Beldjord K; Chevret S; Asnafi V; Huguet F; Boulland ML; Leguay T; Thomas X; Cayuela JM; Grardel N; Chalandon Y; Boissel N; Schaefer B; Delabesse E; Cavé H; Chevallier P; Buzyn A; Fest T; Reman O; Vernant JP; Lhéritier V; Béné MC; Lafage M; Macintyre E; Ifrah N; Dombret H;
Blood; 2014 Jun; 123(24):3739-49. PubMed ID: 24740809
[TBL] [Abstract][Full Text] [Related]
6. Association between measurable residual disease kinetics and outcomes of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Hara R; Onizuka M; Kikkawa E; Shiraiwa S; Harada K; Aoyama Y; Ogiya D; Toyosaki M; Suzuki R; Machida S; Ohmachi K; Ogawa Y; Kawada H; Matsushita H; Ando K
Ann Hematol; 2021 Oct; 100(10):2479-2486. PubMed ID: 34247299
[TBL] [Abstract][Full Text] [Related]
7. Acute lymphoblastic leukemia relapsing after first-line pediatric-inspired therapy: a retrospective GRAALL study.
Desjonquères A; Chevallier P; Thomas X; Huguet F; Leguay T; Bernard M; Bay JO; Tavernier E; Charbonnier A; Isnard F; Hunault M; Turlure P; Renaud M; Bastié JN; Himberlin C; Lepretre S; Lioure B; Lhéritier V; Asnafi V; Beldjord K; Lafage-Pochitaloff M; Béné MC; Ifrah N; Dombret H
Blood Cancer J; 2016 Dec; 6(12):e504. PubMed ID: 27935576
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission.
Nishiwaki S; Inamoto Y; Sakamaki H; Kurokawa M; Iida H; Ogawa H; Fukuda T; Ozawa Y; Kobayashi N; Kasai M; Mori T; Iwato K; Yoshida T; Onizuka M; Kawa K; Morishima Y; Suzuki R; Atsuta Y; Miyamura K
Blood; 2010 Nov; 116(20):4368-75. PubMed ID: 20664060
[TBL] [Abstract][Full Text] [Related]
9. Comparison of autologous and allogeneic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lyu M; Jiang E; He Y; Yang D; Ma Q; Pang A; Zhai W; Wei J; Huang Y; Zhang G; Zhang R; Feng S; Han M
Hematology; 2021 Dec; 26(1):65-74. PubMed ID: 33402056
[No Abstract] [Full Text] [Related]
10. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
Lussana F; Intermesoli T; Gianni F; Boschini C; Masciulli A; Spinelli O; Oldani E; Tosi M; Grassi A; Parolini M; Audisio E; Cattaneo C; Raimondi R; Angelucci E; Cavattoni IM; Scattolin AM; Cortelezzi A; Mannelli F; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Romani C; Bassan R; Rambaldi A
Biol Blood Marrow Transplant; 2016 Nov; 22(11):1983-1987. PubMed ID: 27492792
[TBL] [Abstract][Full Text] [Related]
11. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.
Chalandon Y; Thomas X; Hayette S; Cayuela JM; Abbal C; Huguet F; Raffoux E; Leguay T; Rousselot P; Lepretre S; Escoffre-Barbe M; Maury S; Berthon C; Tavernier E; Lambert JF; Lafage-Pochitaloff M; Lhéritier V; Chevret S; Ifrah N; Dombret H;
Blood; 2015 Jun; 125(24):3711-9. PubMed ID: 25878120
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease.
Bourlon C; Lacayo-Leñero D; Inclán-Alarcón SI; Demichelis-Gómez R
Curr Oncol Rep; 2018 Mar; 20(4):36. PubMed ID: 29577208
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitor prophylaxis after transplant for Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Nishiwaki S; Mizuta S; Ohashi K; Uchida N; Tanaka M; Fukuda T; Ozawa Y; Takahashi S; Onizuka M; Shiratori S; Nakamae H; Kanda Y; Ichinohe T; Atsuta Y; Kako S;
Cancer Sci; 2019 Oct; 110(10):3255-3266. PubMed ID: 31402561
[TBL] [Abstract][Full Text] [Related]
14. High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission.
Candoni A; De Marchi F; Zannier ME; Lazzarotto D; Filì C; Dubbini MV; Rabassi N; Toffoletti E; Lau BW; Fanin R
Leuk Res; 2017 Dec; 63():22-27. PubMed ID: 29096332
[TBL] [Abstract][Full Text] [Related]
15. Monitoring of minimal residual disease after allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia allows for the identification of impending relapse: results of the ALL-BFM-SCT 2003 trial.
Bader P; Kreyenberg H; von Stackelberg A; Eckert C; Salzmann-Manrique E; Meisel R; Poetschger U; Stachel D; Schrappe M; Alten J; Schrauder A; Schulz A; Lang P; Müller I; Albert MH; Willasch AM; Klingebiel TE; Peters C
J Clin Oncol; 2015 Apr; 33(11):1275-84. PubMed ID: 25605857
[TBL] [Abstract][Full Text] [Related]
16. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison.
Cornelissen JJ; van der Holt B; Verhoef GE; van't Veer MB; van Oers MH; Schouten HC; Ossenkoppele G; Sonneveld P; Maertens J; van Marwijk Kooy M; Schaafsma MR; Wijermans PW; Biesma DH; Wittebol S; Voogt PJ; Baars JW; Zachée P; Verdonck LF; Löwenberg B; Dekker AW;
Blood; 2009 Feb; 113(6):1375-82. PubMed ID: 18988865
[TBL] [Abstract][Full Text] [Related]
17. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).
Bassan R; Spinelli O; Oldani E; Intermesoli T; Tosi M; Peruta B; Rossi G; Borlenghi E; Pogliani EM; Terruzzi E; Fabris P; Cassibba V; Lambertenghi-Deliliers G; Cortelezzi A; Bosi A; Gianfaldoni G; Ciceri F; Bernardi M; Gallamini A; Mattei D; Di Bona E; Romani C; Scattolin AM; Barbui T; Rambaldi A
Blood; 2009 Apr; 113(18):4153-62. PubMed ID: 19141862
[TBL] [Abstract][Full Text] [Related]
18. Comparison of haplo-SCT and chemotherapy for young adults with standard-risk Ph-negative acute lymphoblastic leukemia in CR1.
Lv M; Jiang Q; Zhou DB; Hu Y; Liu DH; Wu DP; Wang JB; Jiang H; Wang J; Chang YJ; Wang Y; Zhang XH; Xu LP; Liu KY; Huang XJ
J Hematol Oncol; 2020 May; 13(1):52. PubMed ID: 32414392
[TBL] [Abstract][Full Text] [Related]
19. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.
Nicolini FE; Basak GW; Kim DW; Olavarria E; Pinilla-Ibarz J; Apperley JF; Hughes T; Niederwieser D; Mauro MJ; Chuah C; Hochhaus A; Martinelli G; DerSarkissian M; Duh MS; McGarry LJ; Kantarjian HM; Cortes JE
Cancer; 2017 Aug; 123(15):2875-2880. PubMed ID: 28387926
[TBL] [Abstract][Full Text] [Related]
20. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies.
Gökbuget N; Kneba M; Raff T; Trautmann H; Bartram CR; Arnold R; Fietkau R; Freund M; Ganser A; Ludwig WD; Maschmeyer G; Rieder H; Schwartz S; Serve H; Thiel E; Brüggemann M; Hoelzer D;
Blood; 2012 Aug; 120(9):1868-76. PubMed ID: 22442346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
